Daiwa Securities Group’s Akebia Therapeutics AKBA Stock Holding History

Daiwa Securities Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-316	Closed	–	–	1312
2022 Q3	$0	Hold	316	–	–	﹤0.01%	1333
2022 Q2	$0	Hold	316	–	–	﹤0.01%	1348
2022 Q1	$0	Hold	316	–	–	﹤0.01%	1372
2021 Q4	$1K	Hold	316	–	–	﹤0.01%	1322
2021 Q3	$1K	Hold	316	–	–	﹤0.01%	1258
2021 Q2	$1K	Hold	316	–	–	﹤0.01%	1176
2021 Q1	$1K	Hold	316	–	–	﹤0.01%	1182
2020 Q4	$1K	Sell	316 -489	-61%	-$1.43K	﹤0.01%	1159
2020 Q3	$2K	Buy	805 +65	+9%	+$570	﹤0.01%	1135
2020 Q2	$6K	Hold	740	–	–	﹤0.01%	1094
2020 Q1	$6K	Hold	740	–	–	﹤0.01%	1087
2019 Q4	$5K	Hold	740	–	–	﹤0.01%	1102
2019 Q3	$3K	Hold	740	–	–	﹤0.01%	1100
2019 Q2	$4K	Hold	740	–	–	﹤0.01%	1113
2019 Q1	$6K	Buy	740 +479	+184%	+$3.29K	﹤0.01%	1064
2018 Q4	$1K	Hold	261	–	–	﹤0.01%	1124
2018 Q3	$2K	Hold	261	–	–	﹤0.01%	1121
2018 Q2	$3K	Hold	261	–	–	﹤0.01%	1118
2018 Q1	$2K	Buy	+261	New	+$3.65K	﹤0.01%	1116

Other funds holding AKBA

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCM

Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Daiwa Securities Group's AKBA Position: Q4 2022 in Review

Daiwa Securities Group sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 316 shares.

Daiwa Securities Group first reported a position in AKBA in Q1 2018 and held it in 19 quarters. The position peaked at $6K in Q2 2020. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

Daiwa Securities Group reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
Daiwa Securities Group sold 316 Akebia Therapeutics shares in Q4 2022.
Daiwa Securities Group first reported a position in Akebia Therapeutics in Q1 2018 and held it in 19 quarters.
Daiwa Securities Group's Akebia Therapeutics position peaked at $6K in Q2 2020.
75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.